.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Covington
Healthtrust
Cerilliant
UBS
Novartis
Chubb
Citi
Daiichi Sankyo
Argus Health

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,127,353

« Back to Dashboard

Which drugs does patent 6,127,353 protect, and when does it expire?


Patent 6,127,353 protects NASONEX and is included in one NDA. There has been one Paragraph IV challenge on Nasonex.

Protection for NASONEX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,127,353

Title: Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
Abstract:The invention relates to the novel compound mometasone furoate monohydrate, process for its preparation and pharmaceutical compositions containing said compound.
Inventor(s): Yuen; Pui-Ho (Princeton Junction, NJ), Eckhart; Charles (Kenilworth, NJ), Etlinger; Teresa (Bloomfield, NJ), Levine; Nancy (Flemington, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:07/984,573
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
NASONEX
mometasone furoate
SPRAY, METERED;NASAL020762-001Oct 1, 1997ABRXYesYes6,127,353*PED► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
UBS
Cerilliant
Queensland Health
Deloitte
Baxter
Express Scripts
US Army
Accenture
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot